Should I buy or sell Immunic stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMUX shares. View IMUX analyst ratings or view top-rated stocks .

What is Immunic's stock price target for 2024?

2 equities research analysts have issued twelve-month price objectives for Immunic's shares. Their IMUX share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 620.3% from the stock's current price. View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts .

How have IMUX shares performed in 2024?

Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX stock has decreased by 21.3% and is now trading at $1.18. View the best growth stocks for 2024 here .

Are investors shorting Immunic?

Immunic saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,030,000 shares, an increase of 22.7% from the March 15th total of 2,470,000 shares. Based on an average daily volume of 976,400 shares, the short-interest ratio is presently 3.1 days. View Immunic's Short Interest .

When is Immunic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our IMUX earnings forecast .

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.03.

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , VBI Vaccines (VBIV) , Moderna (MRNA) , CymaBay Therapeutics (CBAY) , NIO (NIO) , NVIDIA (NVDA) , TG Therapeutics (TGTX) and

How do I buy shares of Immunic?

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:IMUX

Immunic (IMUX) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free IMUX Stock Alerts

$1.18

-0.09 (-7.09%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.18
▼
$1.31
50-Day Range: $1.16
▼
$1.53
52-Week Range: $0.95
▼
$3.11

Volume: 365,394 shs
Average Volume: 876,208 shs
Market Capitalization: $106.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.50

Get Immunic alerts:

Immunic MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 620.3% Upside
$8.50 Price Target
Short Interest: Healthy
3.37% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.64
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.98 out of 5 stars

Medical Sector

580th out of 911 stocks

Pharmaceutical Preparations Industry

257th out of 411 stocks

3.5

Analyst's Opinion

Consensus Rating
Immunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Immunic has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.37% of the outstanding shares of Immunic have been sold short.
Short Interest Ratio / Days to Cover
Immunic has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Immunic has recently increased by 22.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Immunic does not currently pay a dividend.
Dividend Growth
Immunic does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for IMUX.

3.7

News and Social Media Coverage

News Sentiment
Immunic has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Immunic this week, compared to 1 article on an average week.
Search Interest
4 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
MarketBeat Follows
4 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunic insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.70% of the stock of Immunic is held by insiders.
Percentage Held by Institutions
51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Immunic are expected to remain at ($0.99) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunic is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunic is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunic has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Immunic Stock (NASDAQ:IMUX)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

IMUX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IMUX Stock News Headlines

April 19, 2024 | finance.yahoo.com

Immunic, Inc. (IMUX)

April 16, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 12, 2024 | morningstar.com

Immunic Inc IMUX

April 5, 2024 | msn.com

Brookline Capital starts Immunic at buy, cites MS drug candidate

April 5, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and Shockwave Medical (SWAV)

April 4, 2024 | finance.yahoo.com

With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors

April 4, 2024 | finance.yahoo.com

Immunic to Host MS R&D Day and Participate in Investor Conferences in April

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 20, 2024 | marketwatch.com

Immunic Gets Allowance for Vidofludimus Calcium Patent Application

March 20, 2024 | proactiveinvestors.com

Immunic granted patent for specific polymorph of vidofludimus calcium in US

March 20, 2024 | prnewswire.com

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States

March 18, 2024 | proactiveinvestors.com

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

March 7, 2024 | prnewswire.com

Immunic to Participate in Investor and Scientific Conferences in March

February 29, 2024 | proactiveinvestors.com

Immunic to present data for lead asset vidofludimus calcium from Phase 2 MS and COVID-19 trials

February 29, 2024 | prnewswire.com

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

February 26, 2024 | markets.businessinsider.com

Hold Rating on Immunic: Balancing Long-Term Potential Against Short-Term Uncertainties

February 23, 2024 | finance.yahoo.com

Immunic Inc (IMUX) Reports Year-End 2023 Financial Results

February 23, 2024 | finance.yahoo.com

Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript

February 22, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Immunic Amid Progress in IMU-838 Trials and Extended Financial Runway

February 22, 2024 | proactiveinvestors.com

Immunic expects financial stability through 2025 as MS clinical programs advance

February 22, 2024 | proactiveinvestors.com

Immunic reports successful 2023 and prepares for key 2025 milestones

February 22, 2024 | finance.yahoo.com

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

February 22, 2024 | prnewswire.com

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

February 21, 2024 | benzinga.com

Immunic Stock (NASDAQ:IMUX) Dividends: History, Yield and Dates

February 21, 2024 | benzinga.com

Immunic's Earnings Outlook

February 15, 2024 | proactiveinvestors.com

Immunic's cutting-edge MS treatment approach: insights from CEO Dr Daniel Vitt

See More Headlines

Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:IMUX
CUSIP: N/A
CIK: 1280776
Web: www.immunic-therapeutics.com
Phone: (332) 255-9818
Fax: 858-673-6843
Employees: 77
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $8.50
High Stock Price Target: $10.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +620.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-93,610,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -157.44%
Return on Assets: -117.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.12
Quick Ratio: 2.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.64 per share
Price / Book: 1.84

Miscellaneous

Outstanding Shares: 89,930,000
Free Float: 87,501,000
Market Cap: $106.12 million
Optionable: Optionable
Beta: 2.07

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Duane D. Nash J.D. (Age 53)
M.B.A., M.D., Executive Chairman
Comp: $433.4k
Dr. Daniel Vitt Ph.D. (Age 56)
CEO, President & Director
Comp: $728.4k
Mr. Glenn Whaley CPA (Age 56)
Chief Financial Officer
Comp: $522.21k
Dr. Andreas Muehler M.D. (Age 59)
Ph.D., Chief Medical Officer
Comp: $599.57k
Dr. Hella Kohlhof (Age 51)
Chief Scientific Officer
Jessica Breu
Head of Investor Relations & Communications
Mr. Inderpal Singh (Age 58)
General Counsel
Mr. Patrick Walsh (Age 41)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IMUX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunic stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMUX shares.
View IMUX analyst ratings or view top-rated stocks.
What is Immunic's stock price target for 2024?: 2 equities research analysts have issued twelve-month price objectives for Immunic's shares. Their IMUX share price targets range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 620.3% from the stock's current price.
View analysts price targets for IMUX or view top-rated stocks among Wall Street analysts.
How have IMUX shares performed in 2024?: Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX stock has decreased by 21.3% and is now trading at $1.18.
View the best growth stocks for 2024 here.
Are investors shorting Immunic?: Immunic saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,030,000 shares, an increase of 22.7% from the March 15th total of 2,470,000 shares. Based on an average daily volume of 976,400 shares, the short-interest ratio is presently 3.1 days.
View Immunic's Short Interest.

When is Immunic's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IMUX earnings forecast.
How were Immunic's earnings last quarter?: Immunic, Inc. (NASDAQ:IMUX) released its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.03.
What other stocks do shareholders of Immunic own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and
How do I buy shares of Immunic?: Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMUX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial